MDNA Life Sciences acquires Mitomic Technology and product pipeline.
MDNA Life Sciences has acquired the intellectual property and assets supporting Mitomics’ product pipeline including the Prostate Core Mitomic Test™ as well as the proprietary development engine, Mitomic Technology™ in order to accelerate its mandate of reducing the burden of disease through the development of low-cost blood-based molecular diagnostics tests offering market-leading accuracy. Says President & CEO George Steinfels, “The successful acquisition and deployment of Mitomics disruptive technology is the cornerstone of MDNA Life Sciences’ growth strategy, focused on critical unmet needs for high burden diseases such as prostate, ovarian and lung cancer as well as endometriosis”.